We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

HIV Binding Simulations Reveal How the Virus Invades the Host Cell Nucleus

By LabMedica International staff writers
Posted on 14 Mar 2016
Print article
Image: The naked HIV capsid, left, would be quickly detected and eliminated from the cell, but a host protein, cyclophilin A, in red in the image on the right, binds to the capsid and enables it to transit through the cell undetected (Photo courtesy of Dr. Juan Perilla, University of Illinois).
Image: The naked HIV capsid, left, would be quickly detected and eliminated from the cell, but a host protein, cyclophilin A, in red in the image on the right, binds to the capsid and enables it to transit through the cell undetected (Photo courtesy of Dr. Juan Perilla, University of Illinois).
A team of molecular virologists has combined advanced cryoelectron microscopy (cryo-EM) with the processing power of two supercomputers to develop a model that explains how HIV interacts with the host cell factor cyclophilin A (peptidylprolyl isomerase A) to invade the nucleus of human cells.

Cyclophilin A is known to interact with several HIV proteins, including p55 gag, Vpr, and capsid protein, and has been shown to be necessary for the formation of infectious HIV virions. As a result, cyclophilin A contributes to viral diseases such as AIDS, hepatitis C, measles, and influenza A.

Researchers have historically relied on NMR and X-ray diffraction techniques to determine the structures of molecular complexes and proteins that play a role in the causes of various disease states. Structural information about a variety of medically important proteins and drugs has been obtained by these methods. Cryo-EM is a complementary analytical technique that provides near-atomic resolution without requirements for crystallization or limits on molecular size and complexity imposed by the other techniques. Cryo-EM allows the observation of specimens that have not been stained or fixed in any way, showing them in their native environment while integrating multiple images to form a three-dimensional model of the sample.

Investigators at the University of Illinois (Urbana-Champaign, USA) used cryo-EM to establish the structure of cyclophilin A in complex with the assembled HIV-1 capsid at a resolution of eight angstroms. The structure exhibited a distinct cyclophilin A-binding pattern in which the cyclophilin A protein selectively bridged the two capsid protein hexamers along the direction of highest curvature.

The investigators then exploited the combined processing power of two supercomputers to simulate interactions between cyclophilin A and the HIV capsid. Building this model required simulating the interactions of some 64 million atoms.

Results, which were confirmed by solid-state NMR analysis, revealed that the cyclophilin A binding pattern was achieved by single cyclophilin A molecules simultaneously interacting with two virion capsid subunits, in different hexamers, through a previously uncharacterized non-canonical interface.

"We have known for some time that cyclophilin A plays a role in HIV infection," said senior author Dr. Klaus Schulten, professor of physics at the University of Illinois. "We knew every atom of the underlying capsid, and then we put the cyclophilin on top of that, of which we also knew every atom. The HIV capsid has to show some of its surface to the nuclear pore complex so that it docks there properly and can inject its genetic material into the nucleus. Now, we understand a little bit better the HIV virus' strategy for evading cellular defenses. That gives insight into battling the system."

The study was published in the March 4, 2016, online edition of the journal Nature Communications.

Related Links:

University of Illinois


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Multi-Function Pipetting Platform
apricot PP5

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.